Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 8940301
Breast tumor treatment with anti-CXCR1 compositions
granted -
US 8940918
Amyloid binding agents
granted -
US 8940713
Micro-RNA family that modulates fibrosis and uses thereof
granted -
US 8940712
Micro-RNA family that modulates fibrosis and uses thereof
granted -
US 8940705
Method of treating disease and selectively modulating transcriptional regulation by a glucocorticoid receptor by administering aclacinomycin and dexamethasone
granted -
US 8940701
Compounds for, and methods of, treating cancer and inhibiting invasion and metastases
granted -
US 8940394
Protein imprinting by means of alginate-based polymers
granted -
US 8936941
Compositions useful for cancer detection and treatment, a cancer stem cell model, and methods of production and use thereof
granted -
US 8937046
Modulating the alternative complement pathway
granted -
US 8936794
Conducting polymer nanotube actuators for precisely controlled release of medicine and bioactive molecules
granted -
US 8936650
Mesh enclosed tissue constructs
granted -
US 8933203
Vault and vault-like carrier molecules
granted -
US 8932583
Scaffolds for cell transplantation
granted -
US 8933193
Lantibiotics and uses thereof
granted -
US 8933201
Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
granted -
US 8932846
Unmarked recombinant intracellular pathogen immunogenic compositions expressing high levels of recombinant proteins
granted -
US 8926966
Cloned glutamic acid decarboxylase
granted -
US 8927750
Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
granted -
US 8927506
Acetates of 2-deoxy monosaccharides with anticancer activity
granted -
US 8927528
Composition for treating hearing loss
granted -
US 8927215
GNA11 mutations in melanoma
granted -
US 8926965
Nucleic acid encoding superoxide dismutase variants and methods of use thereof
granted -
US 8920625
Electrochemical method of making porous particles using a constant current density
granted -
US 8921335
Oral delivery of nucleic acid-based gene interfering agents by Salmonella
granted -
US 8920854
Oral care compositions for treating xerostomia
granted -
US 8920848
Use of cellular extracts for skin rejuvenation
granted -
US 8920799
Methods of treating cancer by administering an Axl ligand-binding portion of an Axl tyrosine kinase receptor extracellular domain
granted -
US 8916519
Influenza A virus vaccines and inhibitors
granted -
US 8916606
Therapeutic compositions and methods for targeted delivery of active agents
granted -
US 8916197
Bone marrow-directing drug delivery materials and their applications
granted -
US 8916603
Methods for treatment with bucindolol based on genetic targeting
granted -
US 8912323
Multifunctional small molecules
granted -
US 8911733
Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
granted -
US 8911743
Haemophilus parasuis polypeptides and methods of use
granted -
US 8911729
Stem cell factor inhibitor
granted -
US 8911722
Modulation of yeast-based immunotherapy products and responses
granted -
US 8911752
Methods of making compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity
granted -
US 8906862
Multiple antigen delivery system using hepatitis E virus-like particle
granted -
US 8906343
PAA nanoplatforms containing fluorophores and targeted moieties covalently linked and photosensitizer post-loaded
granted -
US 8906863
Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
granted -
US 8901095
Selective inhibition of polyglutamine protein expression
granted -
US 8901276
Peptide reagents and methods for detection of colon dysplasia
granted -
US 8900862
Mesh enclosed tissue constructs
granted -
US 8901117
Small molecule inhibitors of MDM2 and the uses thereof
granted -
US 8895539
Pregnancy hormone combination for treatment of autoimmune diseases
granted -
US 8895242
Single molecule nucleic acid nanoparticles
granted -
US 8895055
Telodendrimer nanodiscs without apolipoprotein
granted -
US 8895072
Quantum dot barcode structures and uses thereof
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory